Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 4274

1.

Racial Differences in the Diagnosis and Treatment of Prostate Cancer.

Pietro GD, Chornokur G, Kumar NB, Davis C, Park JY.

Int Neurourol J. 2016 Nov;20(Suppl 2):S112-119. Review.

2.

Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer.

Kilpeläinen TP, Talala K, Raitanen J, Taari K, Kujala P, Tammela TL, Auvinen A.

Am J Epidemiol. 2016 Oct 24. [Epub ahead of print]

PMID:
27777219
3.

Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm.

Halpern JA, Shoag JE, Mittal S, Oromendia C, Ballman KV, Hershman DL, Wright JD, Shih YT, Nguyen PL, Hu JC.

J Urol. 2017 Feb;197(2):363-368. doi: 10.1016/j.juro.2016.08.092.

PMID:
27569432
4.

Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden.

Tomic K, Westerberg M, Robinson D, Garmo H, Stattin P.

Acta Oncol. 2016 Dec;55(12):1461-1466.

PMID:
27749139
5.

Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer.

Kilpeläinen TP, Mäkinen T, Karhunen PJ, Aro J, Lahtela J, Taari K, Talala K, Tammela TL, Auvinen A.

Cancer Epidemiol. 2016 Dec;45:1-5. doi: 10.1016/j.canep.2016.08.022.

PMID:
27636505
6.

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group..

N Engl J Med. 2016 Oct 13;375(15):1415-1424.

7.

Proposal for magnetic resonance imaging-guided salvage radiotherapy for prostate cancer.

Dirix P, van Walle L, Deckers F, Van Mieghem F, Buelens G, Meijnders P, Huget P, Van Laere S.

Acta Oncol. 2017 Jan;56(1):27-32. doi: 10.1080/0284186X.2016.1223342.

PMID:
27587084
8.

[Giant Prostate Carcinoma : A Case Report and Long-Term Outcomes in Japanese Patients].

Furumido J, Abe T, Kikuchi H, Miyajima N, Tsuchiya K, Maruyama S, Shinohara N.

Hinyokika Kiyo. 2016 Jul;62(7):377-81. doi: 10.14989/ActaUrolJap_62_7_377. Review. Japanese.

PMID:
27569357
9.

Active surveillance or radical prostatectomy? Which treatment is best?

Caliskan S, Keles MO, Kaba S, Koca O, Akyuz M, Ozturk MI, Karaman MI.

Bratisl Lek Listy. 2016;117(8):468-71.

PMID:
27546700
10.

Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.

Fossati N, Karnes RJ, Boorjian SA, Moschini M, Morlacco A, Bossi A, Seisen T, Cozzarini C, Fiorino C, Chiorda BN, Gandaglia G, Dell'Oglio P, Joniau S, Tosco L, Shariat S, Goldner G, Hinkelbein W, Bartkowiak D, Haustermans K, Tombal B, Montorsi F, Van Poppel H, Wiegel T, Briganti A.

Eur Urol. 2016 Jul 30. pii: S0302-2838(16)30433-X. doi: 10.1016/j.eururo.2016.07.028. [Epub ahead of print]

PMID:
27484843
11.

Optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy: is ultra-early salvage radiotherapy beneficial?

Taguchi S, Shiraishi K, Fukuhara H, Nakagawa K, Morikawa T, Naito A, Kakutani S, Takeshima Y, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Homma Y.

Radiat Oncol. 2016 Jul 30;11:102. doi: 10.1186/s13014-016-0671-1.

12.

MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.

Yang B, Liu Z, Ning H, Zhang K, Pan D, Ding K, Huang W, Kang XL, Wang Y, Chen X.

Cancer Biomark. 2016 Jul 8;17(2):223-30. doi: 10.3233/CBM-160634.

PMID:
27434290
13.

Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.

Liesenfeld L, Kron M, Gschwend JE, Herkommer K.

J Urol. 2017 Jan;197(1):143-148. doi: 10.1016/j.juro.2016.07.004.

PMID:
27418452
14.

[Alternative antiandrogen therapy for castration-resistant prostate cancer].

Suzuki H, Utsumi T, Endo T, Kamijima S, Kamiya N.

Nihon Rinsho. 2016 May 20;74 Suppl 3:589-94. Japanese. No abstract available.

PMID:
27344799
15.

[LHRH antagonist].

Uemura M.

Nihon Rinsho. 2016 May 20;74 Suppl 3:568-72. Japanese. No abstract available.

PMID:
27344795
16.

Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based Study.

Thorstenson A, Garmo H, Adolfsson J, Bratt O.

J Urol. 2017 Jan;197(1):61-66. doi: 10.1016/j.juro.2016.06.080.

PMID:
27328367
17.

Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy.

Bracci S, Osti MF, Agolli L, Bertaccini L, De Sanctis V, Valeriani M.

Radiat Oncol. 2016 Jun 8;11:78. doi: 10.1186/s13014-016-0656-0.

18.

Expression Levels of MMP9 and PIWIL2 in Prostate Cancer: a Case-Control Study.

Pouyanfar N, Monabbati A, Sharifi AA, Dianatpour M.

Clin Lab. 2016;62(4):651-7.

PMID:
27215085
19.

Evidence of prostate cancer "reverse stage migration" toward more advanced disease at diagnosis: Data from the Pennsylvania Cancer Registry.

Reese AC, Wessel SR, Fisher SG, Mydlo JH.

Urol Oncol. 2016 Aug;34(8):335.e21-8. doi: 10.1016/j.urolonc.2016.03.014.

PMID:
27108226
20.

Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort.

Wong LM, Tang V, Peters J, Costello A, Corcoran N.

BJU Int. 2016 Apr;117 Suppl 4:82-7. doi: 10.1111/bju.13460.

PMID:
27094971
Items per page

Supplemental Content

Loading ...
Support Center